These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Monitoring renal function in children with Fabry disease: comparisons of measured and creatinine-based estimated glomerular filtration rate.
    Author: Tøndel C, Ramaswami U, Aakre KM, Wijburg F, Bouwman M, Svarstad E.
    Journal: Nephrol Dial Transplant; 2010 May; 25(5):1507-13. PubMed ID: 20038520.
    Abstract:
    BACKGROUND: Studies on renal function in children with Fabry disease have mainly been done using estimated creatinine-based glomerular filtration rate (GFR). The aim of this study was to compare estimated creatinine-based GFR (eGFR) with measured GFR (mGFR) in children with Fabry disease and normal renal function. METHODS: Eighty-two examinations were done in 42 children (24 boys, 18 girls) with Fabry disease from three different centres. The mean age was 12.3 years. GFR was measured with iohexol, Cr(51)-EDTA or iothalamate, and the mean mGFR was 108 ml/min/1.73 m(2). RESULTS: The widely used original Schwartz formula (1976) overestimated GFR substantially by 50.6 ml/min/1.73 m(2) with a very low accuracy, whereas the new abbreviated Schwartz formula (2009) showed relatively good performances with a mean GFR overestimation of 5.3 ml/min/1.73 m(2) and 79% of the eGFR calculated within 20% of mGFR, thus being only slightly superior to the Counahan-Barratt formula. However, less than half of the eGFR calculated by the new abbreviated Schwartz equation were within 10% of the mGFR. When repeated measurements were performed, mGFR showed less variation than eGFR. CONCLUSIONS: The new abbreviated Schwartz formula should replace the original Schwartz formula in the routine follow-up of children with Fabry disease. The current creatinine-based GFR formulas are all hampered by low accuracy in the 'creatinine-blind' GFR range, and early progressive disease may be missed. Supplemental mGFR is, therefore, recommended in patients where changes in GFR have potential impact on important treatment regimens. Cystatin C-based GFR formulas remain to be validated in Fabry children.
    [Abstract] [Full Text] [Related] [New Search]